Huntington Bancshares Inc

Huntington Bancshares jumped 1.49% on double-average volume, outperforming regional peers. Q1 net income hit $523M, adjusted EPS 37¢, and Cadence Bank integration wraps in Q2. Management to present at Morgan Stanley June 9.

U.S. mortgage rates edged down slightly, with the 30-year fixed average at 6.43%. However, purchase applications declined and the median monthly payment rose, highlighting ongoing affordability challenges.

Huntington Bancshares shares stabilized around $15.50 as management confirmed its 2026 financial guidance and projected $550 million in stock buybacks for that year, while anticipating significant cost savings from recent acquisitions.

Huntington Bancshares stock rose 0.5% Wednesday, recovering from a prior sell-off, as investors assessed its 2027 EPS target of $1.90-$1.93 and $435M in projected annual cost synergies from recent acquisitions.

Huntington Bank has named Senthil Kumar, previously the top risk officer at BNY, as its new chief risk officer. The move follows the bank's entry into a stricter regulatory category after its merger with Cadence Bank pushed assets to $279 billion.

UniQure shares jumped 78.4% after the FDA said Phase I/II data could support an accelerated-approval filing for its Huntington's disease gene therapy AMT-130. A BLA is planned for Q3 2026.

uniQure shares surged 78% premarket after the FDA agreed to accept three-year Phase I/II data as the basis for an accelerated approval filing for AMT-130 in Huntington's disease, reviving the near-term U.S. path for the potential first disease-modifying treatment.